Strides Arcolab & Gilead Concludes Strategic ARV (Anti Retro Viral) Deal

Strides Arcolab Ltd has announced that the Company has signed a non-exclusive license and technical transfer agreement with US based bio-pharmaceutical Company, Gilead Sciences. This agreement will enable the Company to manufacture and distribute generic versions of Truvada® (emtricitabine and tenofovir disoproxil fumarate) and Vlread® (tenofovir disoproxil fumarate). This agreement provides for the manufacture and distribution of a new generation first line therapy in over 90 countries under the Gilead Access Program. This country classification is rated according to the Human Development Index and includes high prevalence focus countries in Africa and Asia including India.

Mr. Arun Kumar, Vice Chairman and Group CEO of the Company said, this agreement between a global pharmaceutical Company and an emerging Indian pharmaceutical manufacturer highlights our ability to leverage global opportunities. It is indicative of Strides´ ability to align with global Companies´ initiatives to fight HIV/AIDS. This agreement will enable authorized generic versions to be available in eligible countries at a significantly lower cost and consequently lead to substantially larger treatment coverage.

The Company is amongst India´s largest manufacturers of ARV drugs and has a range of products approved by the WHO. The Company has received tentative approval from the US FDA for generic Nevirapine tablets. Several other ARV dossiers are under evaluation by US FDA. The Company is also partnering with the Clinton Foundation to ensure availability of affordable quality generic ARVs in least developed countries.

Source : Equity Bulls

Keywords